Insulin Glargine (rdna Origin) Injection
Insulin glargine is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood) who need insulin to control their diabetes. In people with type 1 diabetes, insulin glargine must be used with another type of insulin (a short-acting insulin). In people with type 2 diabetes, insulin glargine also may be used with another type of insulin or with oral medication(s) for diabetes. Insulin glargine is a long-acting, manmade version of human insulin. Insulin glargine works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes. Insulin glargine comes as a solution (liquid) to inject subcutaneously (under the Continue reading >>
(insulin Glargine Injection) 100 Units/ml?
Prescription Lantus® is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. Do not use Lantus® to treat diabetic ketoacidosis. Do not take Lantus® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus®. Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles. Before starting Lantus®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed. Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus®. Your treatment with TZDs and Lantus® may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including: Sudden weight gain Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, including herbal supplements. Lantus® should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Do NOT dilute or mix Lantus® with any other insulin or solution. It will not work as intended and you may lose blood sugar Continue reading >>
Insulin Glargine
The new long-acting insulin analogue, insulin glargine (‘Lantus’, Aventis Pharma) was approved for use in patients with type 1 and type 2 diabetes mellitus by the US Food and Drug Administration in April, 2000, and by the European Agency for the Evaluation of Medicinal Products in June, 2000. The availability of an insulin preparation that would provide basal insulin requirements has long been awaited.1 However, what kind of long-acting insulin analogue is insulin glargine, is it safe, and if so, how should it best be used? To read this article in full you will need to make a payment Subscribe to The Lancet Continue reading >>
Insulin Glargine
What is the most important information I should know about insulin glargine? Take care not to let your blood sugar get too low. Low blood sugar (hypoglycemia) can occur if you skip a meal, exercise too long, drink alcohol, or are under stress. Symptoms include headache, hunger, weakness, sweating, tremors, irritability, or trouble concentrating. Carry hard candy or glucose tablets with you in case you have low blood sugar. Other sugar sources include orange juice and milk. Be sure your family and close friends know how to help you in an emergency. Also watch for signs of blood sugar that is too high (hyperglycemia). These symptoms include increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, and weight loss. Your blood sugar will need to be checked often, and you may need to adjust your insulin glargine dose. Insulin glargine is only part of a complete program of treatment that may also include diet, exercise, weight control, foot care, eye care, dental care, and testing your blood sugar. Follow your diet, medication, and exercise routines very closely. Changing any of these factors can affect your blood sugar levels. What is insulin glargine? Insulin glargine is a man-made form of a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. Insulin glargine is a long-acting form of insulin that is slightly different from other forms of insulin that are not man-made. Insulin glargine is used to treat type 1 or type 2 diabetes. Insulin glargine may also be used for purposes not listed in this medication guide. What should I discuss with my healthcare provider before using insulin glargine? Do not use this medication if you are allergic to insulin glargine. To make sure y Continue reading >>
Why Isn't Insulin Offered As A Generic Prescription Drug, Even Though It's Been Out For Longer That The Seven Year Patent Time Required For Other Drugs?
The pharmaceutical companies play all sorts of games to keep their patents. They change the formulation slightly, the delivery method, or even the indications for this. They then try to sue anyone who tries to make a generic copy, even when their patent expires. Sometimes, they pay off generic drug makers not to make a drug (illegal, but we know they do this anyways), buy a generic drug maker to prevent this, or even make the generic brand itself, alongside with the name brand. The drug companies in the USA have free reign to charge whatever they want for medication without government interference. When animal insulins were used, a bottle of NPH or Regular insulin cost about $15-$20. When synthetic humulin came out, it probably was about $40-$45. Now, the cost is approaching $200 a bottle sometimes. Why? Because our government is in the pocket of Big Pharm. Absolutely ludicrous! Continue reading >>
- A Patent’s Just Been Granted For What Could Be a Functional ‘Cure’ For Type 1 Diabetes
- The 30-minute op that can save diabetes patients from losing a leg - so why aren't more patients being offered this?
- Is it possible to catch diabetes? It sounds absurd, but that's what a reputable new study suggests. And it may be that other 'lifestyle' diseases such as joint pain and even obesity are contagious, too
Study Says Insulin Glargine May Increase Risk For Breast Cancer
In a recent study, researchers have found that insulin glargine may increase risk for breast cancer in women with type 2 diabetes. Insulin glargine is marketed as Lantus, Basaglar, and Toujeo and is a long-acting or basal insulin treatment used by millions of people worldwide. Researchers sought to find out what association might exist between long-acting insulin analogs and breast cancer risk. They conducted a study on a population-based cohort of 22,395 women all age 40 or over who were taking insulin glargine, insulin detemir, or NPH insulin between 2002 and 2012. They got this data from the UK’s Clinical Practice Research Datalink. The women were tracked until February 2015 or until a breast cancer diagnosis. In their study abstract the authors write that “Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and 95% CIs of incident breast cancer, comparing long-acting insulin analogs with NPH overall, as well as by duration and cumulative dose.” Is Insulin Linked to Higher Breast Cancer Link? Researchers saw 321 incident breast cancer events during the 12 years of follow-up. When compared to NPH insulin, insulin glargine (Lantus, Basaglar, Toujeo) was linked to an increased risk of breast cancer. This risk mostly increased after 5 years of starting insulin glargine and after more than 30 prescriptions for it. The researchers found that the risk was “particularly elevated” in those who were prior insulin users but not for new insulin users. “The risk associated with insulin detemir was not significantly elevated,” write the study authors. The researchers concluded that “Long-term use of insulin glargine is associated with an increased risk of breast cancer in women with type 2 diabetes. The risk associated with insulin de Continue reading >>
Drug: Insulin Glargine
Brite Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] A ALIMENTARY TRACT AND METABOLISM A10 DRUGS USED IN DIABETES A10A INSULINS AND ANALOGUES A10AE Insulins and analogues for injection, long-acting A10AE04 Insulin glargine D03250 Insulin glargine (USAN/INN) USP drug classification [BR:br08302] Blood Glucose Regulators Insulins Insulin glargine D03250 Insulin glargine (USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 24 Hormones 249 Miscellaneous 2492 Pancreatic hormones D03250 Insulin glargine (USAN/INN); Insulin glargine (genetical recombination) (JP17); Insulin glargine (genetical recombination) injection (JP17); Insulin glargine (genetical recombination [Insulin glargin biosimilar 1] (JAN); Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN) Target-based classification of drugs [BR:br08310] Cytokine receptors Receptor tyrosine kinase RTK class II (Insulin receptor family) insulin receptor Insulin glargine D03250 Insulin glargine (USAN/INN) Cytochrome P450 interactions [BR:br08309] CYP inducers CYP1A2 Insulin glargine D03250 Insulin glargine (USAN/INN) Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D03250 Insulin glargine (genetical recombination) D03250 Insulin glargine (genetical recombination) injection Antidiabetics [br08361.html] D03250 New drug approvals in the USA [br08319.html] New Molecular Entity and New Therapeutic Biological Product Approvals D03250 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D03250 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D03250 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D0 Continue reading >>
Insulin Glargine
What is the most important information I should know about insulin glargine? Take care not to let your blood sugar get too low. Low blood sugar (hypoglycemia) can occur if you skip a meal, exercise too long, drink alcohol, or are under stress. Symptoms include headache, hunger, weakness, sweating, tremors, irritability, or trouble concentrating. Carry hard candy or glucose tablets with you in case you have low blood sugar. Other sugar sources include orange juice and milk. Be sure your family and close friends know how to help you in an emergency. Also watch for signs of blood sugar that is too high (hyperglycemia). These symptoms include increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, and weight loss. Your blood sugar will need to be checked often, and you may need to adjust your insulin glargine dose. Insulin glargine is only part of a complete program of treatment that may also include diet, exercise, weight control, foot care, eye care, dental care, and testing your blood sugar. Follow your diet, medication, and exercise routines very closely. Changing any of these factors can affect your blood sugar levels. What is insulin glargine? Insulin glargine is a man-made form of a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. Insulin glargine is a long-acting form of insulin that is slightly different from other forms of insulin that are not man-made. Insulin glargine is used to treat type 1 (insulin-dependent) or type 2 (non insulin-dependent) diabetes. Insulin glargine may also be used for purposes not listed in this medication guide. What should I discuss with my healthcare provider before using insulin glargine? Do not use this medication if you are Continue reading >>
Insulin Glargine, Recombinant (subcutaneous Route)
Side Effects Drug information provided by: Micromedex Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediately if any of the following side effects occur: More common Anxiety behavior change similar to being drunk blurred vision chills cold sweats confusion convulsions (seizures) cool, pale skin difficulty with thinking dizziness or lightheadedness drowsiness excessive hunger fast heartbeat headache nausea nervousness nightmares restless sleep shakiness slurred speech tingling in the hands, feet, lips, or tongue unusual tiredness or weakness Less common or rare Fast pulse skin rash or itching over the entire body sweating trouble breathing Incidence not known Bloating or swelling of the face, hands, lower legs, or feet cough decreased urine difficulty with swallowing dry mouth hives increased thirst irregular heartbeat muscle pain or cramps numbness or tingling in the hands, feet, or lips puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue rapid weight gain vomiting Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: More common Fever sore throat stuffy or runny nose Less common or rare Depression of the skin at the injection site itching, pain, redness, or swelling at the injection site thickening of the skin at injection site Continue reading >>
Insulin Glargine: The First Clinically Useful Extended-acting Insulin In Half A Century?
Insulin glargine (HOE 901) appears to be the first clinically useful extended-acting insulin preparation for 50 years. A combination of a di-arginine addition to the C-terminal of the insulin B-chain, and a glycine substitution in the A-chain, produce an insulin which is soluble at acid pH, but precipitates in sc. tissue at neutral pH after injection. This new insulin analogue has slightly lower receptor binding affinity compared to human insulin, but equal potency in vivo. Prolonged receptor binding is not found, and IGF-1 binding is not significantly different from human insulin. Glucose clamp and sc. disappearance studies confirm that insulin glargine has a much slower onset of effect than NPH (Neutral Protamine Hagedorn) insulin, and a much more protracted profile of action. Variability of absorption is difficult to assess from published studies, but is not dissimilar to NPH insulin. Patient studies in Type 1 and Type 2 diabetes published to date are inconclusive, but appear to confirm differences in pharmacokinetics between insulin glargine and NPH, with significantly lower fasting plasma glucose levels or reduction in night hypoglycaemia. No safety concerns have emerged. It thus appears that insulin glargine is a genuinely new addition to the insulin family, and with further clinical experience it may well be possible to achieve better basal blood glucose control (without enhanced risk of hypoglycaemia), particularly at night or in conjunction with rapid-acting insulin analogues. Continue reading >>
Insulin Detemir Versus Insulin Glargine For Type 2 Diabetes Mellitus
The two long-acting insulin analogues (artificial insulins), insulin detemir or insulin glargine differ in their mechanism of attaining protracted action, leading to possible differences in glycaemic control and safety outcomes. Several studies have compared either insulin detemir or insulin glargine to NPH (Neutral Protamin Hagedorn) insulin. Research directly comparing both long-acting insulin analogues is limited. Our aim was to systematically review the efficacy and safety of insulin detemir and insulin glargine in head-to-head studies in the treatment of type 2 diabetes mellitus. Four studies investigated a total of 2250 people. Trials lasted between 24 and 52 weeks. Overall, risk of bias of the evaluated studies was high. Our analysis of these intermediate term trials comparing insulin detemir with insulin glargine showed that these two insulins were equally effective in achieving and maintaining glycaemic control (glycosylated haemoglobin A1c (HbA1c)). There were no differences in overall, nocturnal and severe hypoglycaemia when comparing insulin detemir to insulin glargine. Insulin detemir was associated with significantly less weight gain (one study showing a difference of 0.9 kg). Treatment with insulin glargine resulted in a lower daily basal insulin dose and a lower number of injection site reactions (1.8% of patients treated with insulin detemir compared to 0.4% of patients treated with insulin glargine had injection side reactions). There was no difference in the variability of fasting glucose levels or the variability of glucose values of 24-hour profiles between the two treatment groups. From the retrieved trials it was not possible to draw conclusions on the effects of these two insulins on quality of life, their costs or on the number of fatalities. On Continue reading >>
What Are The Possible Side Effects Of Insulin Glargine (lantus, Lantus Opticlik Cartridge, Lantus Solostar Pen)?
LANTUS® (insulin glargine) Injection DESCRIPTION LANTUS (insulin glargine injection) is a sterile solution of insulin glargine for subcutaneous use. Insulin glargine is a recombinant human insulin analog that is a long-acting, parenteral blood-glucose-lowering agent [see CLINICAL PHARMACOLOGY]. Insulin glargine has low aqueous solubility at neutral pH. At pH 4 insulin glargine is completely soluble. After injection into the subcutaneous tissue, the acidic solution is neutralized, leading to formation of microprecipitates from which small amounts of insulin glargine are slowly released, resulting in a relatively constant concentration/time profile over 24 hours with no pronounced peak. This profile allows oncedaily dosing as a basal insulin. LANTUS is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, insulin glargine is 21A-Gly-30Ba-L-Arg-3030b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. Insulin glargine has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 Units (3.6378 mg) insulin glargine. The 10 mL vial presentation contains the following inactive ingredients per mL: 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. The 3 mL prefilled pen presentation contains the following inactive ingredients per mL: 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for inje Continue reading >>
What Companies Make The Products That Diabetics, And The Physicians Who Treat Them, Depend On?
Blood Glucose monitoring Systems (Glucometers) Contour TS (Bayer Healthcare) Accu-Chek Active (Roche) Horizon / Ultra / SelectSimple (Johnson and Johnson) Insulin Analogues (insulin receptor ligands) Rapidly absorbed Lispro (Lilly) Aspart (Novo Nordisk) Glulisine (Sanofi Aventis) Steadily absorbed Insulin detemir (Novo Nordisk) Insulin glargine (Sanofi Aventis) Medicines like Metformin, Glitazones etc are available are available from several generic makers. Several orally administered insulin formulations are under clinical trials, we may see some of them in coming decade. Disclaimer: Answers on Quora are not a substitute for medical advise. Continue reading >>
Insulin Glargine.
Abstract BACKGROUND: In diabetes mellitus, the clinical goal of intensive glycemic control (lowering blood glucose concentrations to normal or near-normal levels) has been hindered by the lack of insulin regimens that duplicate the basal-bolus secretion of insulin by the healthy pancreas. In particular, intensive therapy has been associated with a risk of hypoglycemia. OBJECTIVE: This article reviews the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, and potential drug interactions of insulin glargine, a new long-acting recombinant human insulin analogue. Results of clinical trials of its efficacy and tolerability as a basal insulin in the treatment of type 1 and type 2 diabetes are summarized. METHODS: Primary research and review articles on insulin glargine were identified through a search of MEDLINE from 1966 to July 2001. Abstracts were identified through a search of the Institute for Scientific Information Web of Science from 1995 to July 2001 and proceedings of American Diabetes Association scientific meetings. Additional information was obtained from the product information for insulin glargine. All identified articles and abstracts were evaluated for relevance, and all relevant information was included in the review. Priority was given to data from the primary medical literature. RESULTS: Insulin glargine has a slower onset of action than human neutral protamine Hagedorn (NPH) insulin, a longer duration of action (up to 24 hours), and no pronounced peak. It has similar tolerability and produces similar glycemic control to once- or twice-daily human NPH insulin, with a similar glucose-lowering effect on a molar basis. A decreased incidence of hypoglycemia, particularly at night, has been reported with insulin glargine compared with human NPH Continue reading >>
Nci Dictionary Of Cancer Terms
The NCI Dictionary of Cancer Terms features 8,214 terms related to cancer and medicine. We offer a widget that you can add to your website to let users look up cancer-related terms. Get NCI’s Dictionary of Cancer Terms Widget. insulin glargine listen (IN-suh-lin GLAR-jeen) A drug used to control the amount of sugar in the blood of patients with diabetes. It is a form of the hormone insulin that is made in the laboratory. Insulin glargine controls blood sugar longer than insulin does. It is a type of therapeutic insulin. Also called insulin glargine recombinant and Lantus. Continue reading >>
